SI3515924T1 - Kristalinične oblike - Google Patents

Kristalinične oblike

Info

Publication number
SI3515924T1
SI3515924T1 SI201731102T SI201731102T SI3515924T1 SI 3515924 T1 SI3515924 T1 SI 3515924T1 SI 201731102 T SI201731102 T SI 201731102T SI 201731102 T SI201731102 T SI 201731102T SI 3515924 T1 SI3515924 T1 SI 3515924T1
Authority
SI
Slovenia
Prior art keywords
crystalline forms
crystalline
forms
Prior art date
Application number
SI201731102T
Other languages
English (en)
Slovenian (sl)
Inventor
Daniel Leuenberger
Stefan Reber
Raumer Markus Von
Original Assignee
Idorsia Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd. filed Critical Idorsia Pharmaceuticals Ltd.
Publication of SI3515924T1 publication Critical patent/SI3515924T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI201731102T 2016-09-22 2017-09-21 Kristalinične oblike SI3515924T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms
EP17771436.7A EP3515924B1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (1)

Publication Number Publication Date
SI3515924T1 true SI3515924T1 (sl) 2022-04-29

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731102T SI3515924T1 (sl) 2016-09-22 2017-09-21 Kristalinične oblike

Country Status (27)

Country Link
US (4) US10730896B2 (enExample)
EP (2) EP3981774A1 (enExample)
JP (1) JP7097369B2 (enExample)
KR (1) KR102552795B1 (enExample)
CN (1) CN109715639B (enExample)
AU (1) AU2017331930B2 (enExample)
CA (1) CA3037794A1 (enExample)
CL (1) CL2019000728A1 (enExample)
CY (1) CY1125052T1 (enExample)
DK (1) DK3515924T3 (enExample)
EA (1) EA201990723A1 (enExample)
ES (1) ES2908572T3 (enExample)
HR (1) HRP20220234T1 (enExample)
HU (1) HUE057772T2 (enExample)
IL (1) IL265445B2 (enExample)
LT (1) LT3515924T (enExample)
MA (1) MA46266B1 (enExample)
MX (1) MX381590B (enExample)
MY (1) MY193080A (enExample)
PH (1) PH12019500567B1 (enExample)
PL (1) PL3515924T3 (enExample)
PT (1) PT3515924T (enExample)
RS (1) RS62946B1 (enExample)
SI (1) SI3515924T1 (enExample)
TW (1) TWI752086B (enExample)
UA (1) UA124073C2 (enExample)
WO (1) WO2018055016A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057772T2 (hu) 2016-09-22 2022-06-28 Idorsia Pharmaceuticals Ltd Kristályos formák
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
DK4181872T3 (da) 2020-07-15 2026-01-26 Viatris Asia Pacific Pte Ltd Vandig, farmaceutisk sammensætning omfattende en p2y12 receptorantagonist
MX2024000653A (es) * 2021-07-13 2024-01-31 Idorsia Pharmaceuticals Ltd Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
US6855715B1 (en) 1999-06-14 2005-02-15 Eli Lilly And Company Serine protease inhibitors
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
CA2507657C (en) 2002-12-11 2011-05-31 Bayer Schering Pharma Aktiengesellschaft 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
PT1611144E (pt) 2003-04-09 2010-11-12 Wyeth Llc Derivados do ácido 2-(8,9-dioxo-2,6-diazabiciclo(5.2.0)- non-1(7)-eno-2-il)-alquil-fosfónico e sua utilização como antagonistas do receptor n-metil-d-aspartato (nmda)
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
ES2421448T3 (es) 2005-10-21 2013-09-02 Actelion Pharmaceuticals Ltd Derivados de piperazina como agentes contra la malaria
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CA2684644A1 (en) 2007-04-23 2008-10-30 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
BRPI0819696B1 (pt) 2007-11-29 2018-10-23 Actelion Pharmaceuticals Ltd compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
JP5504171B2 (ja) 2007-12-26 2014-05-28 サノフイ P2y12アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
JP5560202B2 (ja) 2007-12-26 2014-07-23 サノフイ P2y12拮抗薬としてのピラゾール−カルボキサミド誘導体
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
WO2010116328A2 (en) 2009-04-08 2010-10-14 Actelion Pharmaceuticals Ltd 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
KR101728180B1 (ko) 2009-04-22 2017-04-18 액테리온 파마슈티칼 리미티드 티아졸 유도체들 및 p2y12 수용체 길항제로서 이들의 용도
HUE057772T2 (hu) 2016-09-22 2022-06-28 Idorsia Pharmaceuticals Ltd Kristályos formák
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
DK4181872T3 (da) 2020-07-15 2026-01-26 Viatris Asia Pacific Pte Ltd Vandig, farmaceutisk sammensætning omfattende en p2y12 receptorantagonist

Also Published As

Publication number Publication date
US20210009614A1 (en) 2021-01-14
LT3515924T (lt) 2022-03-10
JP7097369B2 (ja) 2022-07-07
US20250163086A1 (en) 2025-05-22
UA124073C2 (uk) 2021-07-14
IL265445B2 (en) 2024-05-01
JP2019529553A (ja) 2019-10-17
PH12019500567A1 (en) 2019-11-18
IL265445B1 (en) 2024-01-01
TWI752086B (zh) 2022-01-11
US20220275011A1 (en) 2022-09-01
MA46266B1 (fr) 2022-02-28
DK3515924T3 (da) 2022-03-21
MA46266A (fr) 2019-07-31
US10730896B2 (en) 2020-08-04
RS62946B1 (sr) 2022-03-31
CN109715639A (zh) 2019-05-03
KR102552795B1 (ko) 2023-07-06
CA3037794A1 (en) 2018-03-29
PH12019500567B1 (en) 2024-01-31
US20200017534A1 (en) 2020-01-16
EP3981774A1 (en) 2022-04-13
US11365209B2 (en) 2022-06-21
MX2019003093A (es) 2019-07-18
WO2018055016A1 (en) 2018-03-29
US12227532B2 (en) 2025-02-18
MX381590B (es) 2025-03-12
AU2017331930B2 (en) 2021-07-15
EA201990723A1 (ru) 2019-10-31
TW201813965A (zh) 2018-04-16
HUE057772T2 (hu) 2022-06-28
EP3515924A1 (en) 2019-07-31
MY193080A (en) 2022-09-26
BR112019004845A2 (pt) 2019-06-04
HRP20220234T1 (hr) 2022-05-13
EP3515924B1 (en) 2021-12-15
IL265445A (en) 2019-05-30
CN109715639B (zh) 2022-04-19
PL3515924T3 (pl) 2022-04-11
NZ750772A (en) 2023-10-27
PT3515924T (pt) 2022-03-11
ES2908572T3 (es) 2022-05-03
KR20190052704A (ko) 2019-05-16
CL2019000728A1 (es) 2019-07-05
AU2017331930A1 (en) 2019-03-07
CY1125052T1 (el) 2024-02-16

Similar Documents

Publication Publication Date Title
IL273730A (en) crystalline forms
AU201616678S (en) Cylindres
DK3270751T3 (en) Foodprocessor
SG10201911417PA (en) Crystalline compounds
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
IL262674A (en) crystals
GB201614939D0 (en) Crystalline hydrate
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
HUE066360T2 (hu) Eravaciklin kristályformái
GB201419174D0 (en) Crystalline forms
IL265445A (en) crystalline forms
IL253479A0 (en) Crystalline forms of efinconazole
PT3390358T (pt) Bis-cloridrato de eravaciclina cristalino
PL3350179T3 (pl) Krystaliczne postacie
AU201713059S (en) SUNSHADE - square
ZA201902553B (en) Crystalline forms
IL261795A (en) Crystalline form
GB201715010D0 (en) Crystalline forms
GB201708856D0 (en) Seletalisib crystalline forms
HK40009744A (en) Crystalline forms
GB201604759D0 (en) Crystalline compounds
GB201704789D0 (en) Crystalline compounds
AU5499P (en) T15-1218 Bituminaria bituminosa
AU201713060S (en) SUNSHADE - triangle
AU2016376V (en) NinbellaPurple Alyogyne huegelii